Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

When it comes to redrawing the boundaries of what proteins are druggable, small molecules have soaked up the spotlight. Hordes of new entrants — inhibitors, allosteric modulators, degraders — promise to make a big difference by hitting disease-causing proteins at the right spot.

Over the last five years a biotech...

Click to view original post